Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer (Q34254837)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

0 references

0 references

pancreatic cancer

1 reference

based on heuristic

inferred from title

James Lewis Abbruzzese

5

object named as

James L Abbruzzese

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

6

object named as

Donghui Li

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

2

object named as

Milind Javle

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Motofumi Tanaka

1

object named as

Motofumi Tanaka

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

3

object named as

Xiaoqun Dong

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

4

object named as

Cathy Eng

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

language of work or name

0 references

publication date

1 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

116

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

22

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

5325-5335

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

A "silent" polymorphism in the MDR1 gene changes substrate specificity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Cellular pharmacology of gemcitabine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Assessing the probability that a positive report is false: an approach for molecular epidemiology studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Drug resistance to 5-aza-2'-deoxycytidine, 2',2'-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

6 July 2018

Pancreatic cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25282

21 January 2018

Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25282

21 January 2018

The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25282

21 January 2018

Association between single nucleotide polymorphisms in deoxycytidine kinase and treatment response among acute myeloid leukaemia patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25282

21 January 2018

Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25282

21 January 2018

RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25282

21 January 2018

Identification of functional single nucleotide polymorphism haplotypes in the cytidine deaminase promoter

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25282

21 January 2018

Staging of pancreatic cancer with multidetector CT in the setting of preoperative chemoradiation therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25282

21 January 2018

A functional single-nucleotide polymorphism in the human cytidine deaminase gene contributing to ara-C sensitivity.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25282

21 January 2018

Structural and functional analysis of the cytidine deaminase gene in patients with acute myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25282

21 January 2018

Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25282

21 January 2018

Functional characterization in yeast of genetic variants in the human equilibrative nucleoside transporter, ENT1

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25282

21 January 2018

Functional single nucleotide polymorphism haplotypes in the human equilibrative nucleoside transporter 1.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25282

21 January 2018

Ribonucleotide reductase subunit one as gene therapy target: commentary re: M-Y. Cao et al., Adenovirus-mediated ribonucleotide reductase R1 gene therapy of human colon adenocarcinoma. Clin. Cancer Res., 9: 4304-4308, 2003.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

28 October 2018

Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

28 October 2018

Recombinant gene products of two natural variants of the human cytidine deaminase gene confer different deamination rates of cytarabine in vitro.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2966859

28 October 2018

Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25282

21 January 2018

2'-Deoxy-2'-methylenecytidine and 2'-deoxy-2',2'-difluorocytidine 5'-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase

1 reference

https://pubmed.ncbi.nlm.nih.gov/20665488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism

1 reference

https://pubmed.ncbi.nlm.nih.gov/20665488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1)

1 reference

https://pubmed.ncbi.nlm.nih.gov/20665488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism

1 reference

https://pubmed.ncbi.nlm.nih.gov/20665488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20665488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Gemcitabine pharmacogenomics: cytidine deaminase and deoxycytidylate deaminase gene resequencing and functional genomics

1 reference

https://pubmed.ncbi.nlm.nih.gov/20665488

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CNCR.25282

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34254837&oldid=1967316135"